Eisai broke ground for a new pharmaceutical production and formulation R&D facility for parenteral, or intravenous, oncology treatments in Research Triangle Park. Eisai has a number of drugs in development for patients with cancer and recently entered the market through the acquisition of four oncology-related products from Ligand Pharmaceuticals.
"Currently, Eisai is studying various anticancer compounds," remarks Ray Wood, vp, pharmaceutical and analytical R&D. "The new facility will further enhance our capabilities to develop and produce drug formulations for clinical trials, an important step in introducing Eisai's future oncology products."
Eisai will invest $90 million in the 65,000-sq-ft facility, which will encompass aseptic processing suites, laboratories, and other support functions. In addition, a separate $15-million central utilities building is planned to supply power, steam, chilled water, and compressed air to existing and new operations. Facility completion is anticipated in three years with operations beginning in 2009, leading to 59 new jobs over the next three years and a total of 84 new jobs over the next five years.
The new facility will complement the existing 190,000-sq-ft structure, which is devoted to manufacturing Aricept® and Aciphex® tablets as well as formulation R&D and manufacturing of compounds for use in clinical trials.